Abstract 66P
Background
Glioblastoma is the most common primary malignancy of the brain, affecting approximately 3 per 100 000 people, with a median overall survival of 15 months. Tumor-associated macrophages comprise up to 30% of the glioblastoma tumor microenvironment (TME) and consist of microglia and monocyte-derived macrophages (MDM). MDM arise from granulocyte-monocyte progenitors (GMP) or monocyte-dendritic cell progenitors (MDP). Our recent work identified a unique macrophage population expressing myeloperoxidase (MPO) and other GMP-associated genes associated with long-term survival in glioblastoma patients. ScRNA-seq analysis suggests that MPO+ macrophages may arise from GMPs and are metabolically distinct from MPO- MDM. Interestingly, adoptive transfer of GMP- versus MDP-derived monocytes into glioma-bearing mice had opposing effects on tumor growth. GMP-lineages specifically delayed tumor growth—aligning with our correlative findings in patients. The role of metabolic changes on the anti-tumor function of MDM of distinct developmental lineages remains unknown. We hypothesize that metabolic differences between GMP- and MDP-derived MDM may shift nutrient partitioning within the TME.
Methods
Bulk RNA-seq of GMP- and MDP-MDM was performed. To functionally assess metabolic differences between GMP- and MDP-MDM, Seahorse XFe96 analysis as well as metabolite analysis of conditioned media will be performed.
Results
Bulk RNA-seq of GMP- and MDP-MDM showed differential expression of many metabolic pathways, notably, a downregulation of the pentose phosphate pathway and aerobic respiration in GMP-MDM compared to MDP-MDM. Furthermore, co-culturing GMP- or MDP-MDM with GL261 glioma cell line suggests GMP-MDM are more phagocytic towards tumor cells. We will perform Seahorse XFe96 analysis and metabolite analysis of the conditioned media from GMP-MDM vs. MDP-MDM to investigate the functional impact of metabolic differences further.
Conclusions
Understanding how metabolic differences of MDM derived from different lineages shift nutrient competition in the TME will lead to a better understanding of the roles of macrophages in the TME.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract